ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.65+0.06 (+1.67%)
Close on Nov 17, 2026Market cap $362.98MP/E –Yield –
ARS Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ARS Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$216.27M. For fiscal 2025 it was -$179.45M. The highest annual figure on record is -$3.08M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$179.45M | – |
| FY2024 | Dec 31, 2024 | -$3.08M | – |
| FY2023 | Dec 31, 2023 | -$67.52M | – |
| FY2022 | Dec 31, 2022 | -$35.52M | – |
| FY2021 | Dec 31, 2021 | -$19.45M | – |
| FY2020 | Dec 31, 2020 | -$32.92M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$61.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$60.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.47M | -187.9% |
| Q3 FY2025 | Sep 30, 2025 | -$53.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.18M | – |
| Q4 FY2024 | Dec 31, 2024 | $47.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.44M | -133.1% |
| Q3 FY2022 | Sep 30, 2022 | -$6.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.10M | – |
| Q4 FY2021 | Dec 31, 2021 | $46.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.89M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.11M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.24M | – |
See a number that looks wrong?